Related Experiment Video
Updated: Aug 8, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Therapeutic options for hormone-refractory prostate cancer]
K Miller1, C Börgermann, J Thüroff
1Urologische Klinik, Charité, Campus Benjamin Franklin, Universitätsmedizin, Hindenburgdamm 30, 12200, Berlin, Germany. kurt.miller@charite.de
Der Urologe. Ausg. A
|May 20, 2006
Summary
Docetaxel offers a survival benefit for hormone-refractory prostate cancer patients, improving pain and quality of life. Zoledronic acid effectively reduces skeletal complications in those with bone metastases.
Area of Science:
- Oncology
- Medical Oncology
Background:
- Hormone-refractory prostate cancer was historically considered chemoresistant.
- Bone metastases significantly impact morbidity, causing pain and skeletal complications.
Purpose of the Study:
- To evaluate the efficacy of docetaxel in hormone-refractory prostate cancer.
- To assess the impact of zoledronic acid on skeletal complications in metastatic prostate cancer.
Main Methods:
- Phase III trial comparing docetaxel (75 mg/m(2) every 3 weeks) with mitoxantrone.
- Study evaluating zoledronic acid (4 mg) versus placebo for bone metastases.
Main Results:
- Docetaxel demonstrated improved median survival (18.9 vs. 16.5 months) and enhanced quality of life compared to mitoxantrone.
- Zoledronic acid significantly reduced skeletal complications, particularly pathological fractures.
- Common side effects included neutropenia for docetaxel and flu-like symptoms for zoledronic acid.
Conclusions:
- Docetaxel is now a standard treatment for hormone-refractory prostate cancer, showing survival benefits.
- Zoledronic acid is a standard treatment for hormone-refractory prostate cancer with bone metastases, reducing skeletal morbidity.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...